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VCAM-1 (vascular cell adhesion molecule-1) and Sox18
are involved in vascular development. VCAM-1 is an
important adhesion molecule that is expressed on endo-
thelial cells and has a critical role in endothelial activa-
tion, inflammation, lymphatic pathophysiology, and
atherogenesis. The Sry-related high mobility group box
factor Sox18 has previously been implicated in endothe-
lial pathologies. Mutations in human and mouse Sox18
leads to hypotrichosis and lymphedema. Furthermore,
both Sox18 and VCAM-1 have very similar spatio-tempo-
ral patterns of expression, which is suggestive of cross-
talk. We use biochemical techniques, cell culture systems,
and the ragged opossum (RaOP) mouse model with a nat-
urally occurring mutation in Sox18 to demonstrate that
VCAM-1 is an important target of Sox18. Transfection,
site-specific mutagenesis, and gel shift analyses demon-
strated that Sox18 directly targeted and trans-activated
VCAM-1 expression. Importantly, the naturally occurring
Sox18 mutant attenuates the expression and activation of
VCAM-1 in vitro. Furthermore, in vivo quantitation of
VCAM-1 mRNA levels in wild type and RaOP mice dem-
onstrates that RaOP animals show a dramatic and signif-
icant reduction in VCAM-1 mRNA expression in lung,
skin, and skeletal muscle. Our observation that the
VCAM-1 gene is an important target of SOX18 provides the
first molecular insights into the vascular abnormalities in
the mouse mutant ragged and the human hypotrichosis-
lymphedema-telangiectasia disorder.
The formation of blood vessels occurs through two distinct
mechanisms, vasculogenesis and angiogenesis (1). Vasculogen-
esis leads to the vascularization of the endodermally derived
organs such as lung, intestine, spleen, liver, and stomach,
whereas angiogenesis involves the vascularization of the or-
gans of mesodermal and ectodermal origin such as the limbs,
kidney, and the brain. It also gives rise to the intersomitic and
vertebral arteries (2).
We have recently implicated Sox18 in vascular development
(10). Sox18 is a member of the Sry-related HMG1 box-contain-
ing (Sox) family of transcription factors. SOX proteins bind to
DNA in a sequence-specific manner via the HMG domain, with
all the proteins characterized to date binding to the heptameric
motif (A/T)(A/T)CAA(A/T)G (11). We have shown previously
that Sox18 binds to the consensus sequence AACAAAG and
trans-activates a heterologous promoter containing this
element (12).
The Sox family displays both overlapping and distinct spatio-
temporal expression patterns during embryogenesis and devel-
opment. Aberrant Sox expression, mutation, or disruption
leads to a number of diseases; for example, Sry and Sox9 are
involved in sex reversal (13, 14).
The situation is similar for Sox18. In situ analysis of Sox18
has demonstrated expression in the mesenchyme underlying
the developing hair follicle, in the presumptive heart, and in
the developing vasculature (10). The naturally occurring mouse
mutant ragged (Ra) of which there are four allelic variants, Ra,
ragged Jackson (RaJ), ragged-like (Ragl) and RaOP, all contain
mutations in Sox18 (15). All these mutants display defects in
hair and skin development. However, most life threatening is
the generalized edema suffered by these animals (16), which is
probably due to lymphatic aberrations (17–19).
Recently, a report has been published describing the investi-
gation of several mutations in SOX18 and the hypotrichosis-
lymphedema-telangiectasia (HLT) disorder in humans (20). Pa-
tients present with early onset alopecia of the scalp and
lymphedema. The most severe lymphatic abnormality presented
was non-immune hydrops fetalis (of unknown etiology). Telangi-
ectasia was present in only in some of the patients studied, as
were other anomalies such as thinness and transparency of the
skin, hydrocele, and cutaneous papular vascular lesions.
One of the major functions for the blood and lymphatic vas-
cular system is to provide efficient access for leukocytes and
other immune system molecules to all tissues of larger animals.
The immune system responds to damage or illness via the
accumulation of leukocytes, leading to a localized inflammation
in the diseased area. This inflammatory response is necessarily
tightly coordinated, as the lack of control can itself lead to
various diseases, for example arthritis, psoriasis, multiple scle-
rosis, asthma, atherosclerosis, and allergy (21–24). Of the mul-
titude of proteins involved in the immune system response, the
cell adhesion molecules play a major role in mediating immune
function and inflammation (25).
Vascular cell adhesion molecule-1 (VCAM-1), a member of
* This project was supported by a grant from the National Health and
Medical Research Council of Australia. The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ An Australian Research Council Professorial Research Fellow.
§ A National Health and Medical Research Council (NHMRC) Prin-
cipal Research Fellow and to whom correspondence should be ad-
dressed. Fax: 61-7-3346-2101; E-mail: g.muscat@imb.uq.edu.au.
1 The abbreviations used are: HMG, high mobility group; Sox, Sry-
related HMG box-containing (protein); VCAM-1, vascular cell adhesion
molecule-1; IRF-2, interferon regulatory factor-2; Ra, ragged; RaJ,
ragged Jackson; Ragl, ragged-like; RaOP, ragged opossum; RT, reverse
transcription; EMSA, electrophoretic mobility shift assay; GST, gluta-
thione S-transferase; aa, amino acids.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 7, Issue of February 13, pp. 5314–5322, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org5314
 at UQ Library on October 11, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the immunoglobin gene superfamily of cell adhesion molecules,
is expressed on the cell surface of activated endothelia, in the
skin (26, 27), and in developing muscle and the lung (28–30).
VCAM-1 recognizes the integrin receptors 41 (31) and 47
(32, 33) present on monocytes, eosinophils, and lymphocytes,
whereas VCAM-1-deficient embryos die in utero due to ab-
normalities in chorio-allantoic fusion (34). In vivo animal
studies demonstrate that attenuated VCAM-1 function in
mice provided protection against atherosclerosis. For exam-
ple, mice with reduced (not ablated) VCAM-1 expression and
function crossed with low density lipoprotein receptor
LDLR/ mice prone to atherosclerosis produce animals
resistant to atherogenesis (35).
Much of the previous research has focused on the control of
VCAM-1 expression via extracellular signals. For example, li-
popolysaccharide and cytokines such as interleukin-4 (IL-4),
tumor necrosis factor- (TNF-) (36, 37), interferon- (INF-),
transforming growth factor-1 (TGF-1) (38), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (39), and vas-
cular endothelial growth factor (VEGF) (40) cause an increase
in the level of expression of VCAM-1 in endothelia as well as in
other cell types, whereas angiopoietin 1 (ang1) can repress the
activation of VCAM-1 by vascular endothelial growth factor
(41).
In contrast, transcriptional regulation of VCAM-1 is less well
understood. Most notable is the role of interferon regulatory
factor-2 (IRF-2) in the control of VCAM-1 expression in muscle
(42).
Sox factors act as critical regulators of organ ontogeny via
the modulation of expression of particular target genes. Sur-
prisingly, relatively few target genes for this family of tran-
scription factors have been described in the literature (11).
Therefore, to elucidate the function of Sox18 in the blood and
lymphatic vascular system, the major site of expression and of
abnormality in the ragged animal, it is important to find target
genes in this organ.
Our study demonstrates that native Sox18 (and not the
mutant ragged form) is able to induce the activity of the
VCAM-1 promoter. In biochemical assays we identified and
characterized three Sox18 binding sites. However, we demon-
strated that only the SoxB site at 715 is necessary for
VCAM-1 trans-activation. In vivo validation of this data was
obtained from the RaOP animals that have very significantly
reduced levels (8–40-fold) of VCAM-1 expression (and not
other adhesion molecules, including ICAM-1 and ICAM-2,
JCAM, NCAM-1, and PECAM-1).
MATERIALS AND METHODS
RNA and cDNA Preparation—RNA for realtime PCR was isolated
from organs of RaOP and wild-type adult male siblings as described
previously (45), with the exception that the lyophilized RNA was puri-
fied by processing 100 g through a Qiagen RNeasy mini column.
During this purification process the RNA was DNase-treated. Quanti-
tation of the purified RNA was carried out as described previously (45).
First strand cDNA synthesis was carried out using 5 g of purified RNA
and primed with oligo(dT)18, using the Superscript III enzyme and the
supplied manufacturer’s protocol.
Real Time PCR—Target cDNA levels were quantitated by real time
RT-PCR using an ABI Prism™ 7700 Sequence Detector system utilizing
SYBR Green I (Molecular Probes, Eugene OR; used at 0.8) as a
nonspecific PCR product fluorescence label. Quantitation was 45 cy-
cles of 95 °C for 15 s and 60 °C for 1 min two-step thermal cycling
preceded by an initial 95 °C for 2 min for activation of 0.75 units of
Platinum® TaqDNA polymerase (Invitrogen). The 25-l reaction also
contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl2, 200 M
each of dGTP, dATP, and dCTP, 400 M dUTP, 0.5 units of uracil-N-
glycosylase, 500 nM ROX reference dye (Invitrogen), and 200 nM each
forward and reverse primers. Mus musculus primer sequences for
VCAM-1 are as follows: forward, 5-TGACAAGTCCCCATCGTTGA-3;
reverse, 5-ACCTCGCGACGGCATAATT-3.
Promoter Construct Generation—The sequence of the murine
VCAM-1 promoter has been published elsewhere (46) and is available
on NCBI (accession number U42327). Mouse genomic DNA (C57BL/6)
was a gift from J. Rowland, and 10 ng was used in the outer PCR
amplification to generate the VCAM-1 promoter. Nested PCR was nec-
essary for amplification of the 1895-bp promoter that has been pub-
lished previously. Outer primers were constructed at the published
upstream limit of murine VCAM-1 promoter at 1895 bp and within
the first exon at 19 bp. The outer PCR was performed with 100 ng of
each primer (1895, 5-GCCGGTACCGATCTACATAGCCACG-
GAGAG-3; and 19, 5-CGACCATCTTCACAGGCATTT-3), 1.25 units
of Pfu®, and 0.2 mM dNTPs in a final volume of 50 l containing the
supplied buffer (Promega). Hot start PCR was performed at 95 °C for 5
min followed by 35 cycles of 95 °C for 1 min, 60 °C for 1 min, and 68 °C
for 4 min. The inner primers were constructed such that the 5-primer
at 1889 contained the restriction enzyme site KpnI (1887, 5-CGG-
GGTACCATAGCCACGGAGAGTTCTT-3), whereas, the 3-primer had
the restriction enzyme site XhoI (1, 5-GCCCTCGAGTTCAAGTCTC-
TGCTTCAAAGCC-3). 1 l of the outer PCR was combined with buffer
B and 0.25 units of polymerase mix from the Fail-Safe PCR system
(Epicenter) and 100 ng of each inner primer in a final volume of 10 l.
The VCAM-1 inner PCR profile was the same as that used for the
outer PCR.
The product was digested with KpnI and XhoI, inserted into pGL2-
Basic (pGL2B-Promega), and sequenced completely via automated se-
quencing using the ABI system and reagents. This clone was then used
as the parental plasmid to generate all other sub-clones. Deletion clones
were generated either by restriction digests or PCR amplification.
VC1219 was generated by restriction digest with PstI and KpnI, and
the vector plus the remaining insert were then blunt-ended with Kle-
now (New England Biolabs) and religated. Both VC754 and 504 were
generated via PCR amplification with the primers 5-GACTTCCTGT-
CATCCAGCAATGGGTCAAA-3 and 5-CGGGGTACCTTTGTTGAAA-
GAG-3, respectively. The 3-primer was the inner primer 1 from the
initial nested PCR. The PCR profile was essentially the same as that
done for the nested PCR, with the exception that the annealing tem-
perature was 55 °C. Site-directed mutagenesis of the VCAM-1 promoter
was undertaken via the QuikChange® II kit from Stratagene and
carried out according to the manufacturer’s protocol. The primers used
for the 1569 mutation are 5-ATGACATGACATCATTGAGGTC-
CTCTAG-3 and 5-CTAGAGGACCTCAATGATGTCATGTCAT-3. The
primers used for the 715 mutation are 5-GCTGGGGCATCATCAAA-
CAAAA-3 and 5-TTTTGTTTGATGATGCCCCAG-3.
Cell Culture and Transient Transfections—COS-1 (simian fibroblast)
and SVEC4-10 (mouse high venule endothelial) cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum in 6% CO2. C2C12 (mouse skeletal muscle) cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 20% fetal calf
serum in 6% CO2. Cells for transfection were grown in 24-well dishes to
50–60% confluence before being transiently transfected with 2 g of the
reporter plasmid and 1 g of the expression plasmids in 0.5 ml of
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum by
a liposome-mediated procedure. Briefly, SVEC4-10 cells were trans-
fected using N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethylammonium pro-
pane methylsulfate (DOTAP) (Roche Molecular Biochemicals) in quan-
tities 6-fold (v/w) the total amount of DNA, whereas COS-1 and C2C12
cells were transfected using 15 l of DOTAP and 10 l of 1,3-di-
oleoyloxy-2-(6-carboxyspermyl)-propylamid (DOSPER) (Roche Molecu-
lar Biochemicals). 24 h post-transfection the medium was replaced, and
the cells were grown for a further 24–48 h. Each experiment repre-
sented at least two sets of independent quadruplicates to overcome the
variability inherent in transfections. Cells were harvested and assayed
for luciferase activity as described previously (47).
Electrophoretic Mobility Shift Assay (EMSA)—We have described
previously the cloning and protein expression of a murine Sox 18 fusion
construct with glutathione-S-transferase (GST) using the pGEX-1 bac-
terial expression vector (12). Briefly, Escherichia coli DH5a cells con-
taining this vector were induced for 1–2 h with 0.5 mM isopropyl
thiogalactoside after the cells had grown to an A600 of 0.6. The pelleted
cells were sonicated, and the cleared lysate containing the fusion pro-
tein was loaded onto glutathione-agarose columns in Dignam buffer C
(containing protease inhibitors) (47). After extensive column washing,
the fusion protein was eluted with Dignam buffer C supplemented with
5 mM reduced glutathione.
Probes used in all EMSAs were annealed and then radiolabeled using
-32P and T4 polynucleotide kinase (PNK). The oligonucleotide se-
quences used as probes are as follows: 1569, 5-TTTTATGACATGA-
CattgttGAGGTCCTC-3 (top strand) and 5-GAGGACCTCaacaatGTC-
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ATGTCATAAAA-3 (bottom strand); 715, 5-GGCTGGGGCattgtcAA-
ACAAAAG-3 (top strand) and 5-CTTTTGTTTgacaatGCCCCAGCC-3
(bottom strand); 491, 5-GAAAGAGaacaatTTTTATTTTTTAAATTG-
CAAATGCATTTCTT-3 (top strand) and 5-AAGAAATGCATTTGCAA-
TTTAAAAAATAAAAattgttCTCTTTC-3 (bottom strand).
The bases in lowercase letters represent the putative Sox binding
sites. All EMSA experiments were carried out in a total of 20 l in
Dignam Buffer C containing 1–2 ng of T4 polynucleotide kinase-labeled
probe and 2 g of the purified, bacterially expressed GST-Sox 18. The
assays were incubated at room temperature for 20 min and electro-
phoresed through a 6% (polyacrylamide/bisacrylamide; 20:1) gel in 80
mM Tris borate and 2 mM EDTA. Gels were briefly soaked in 10% acetic
acid, dried, and autoradiographed.
Competition EMSAs were carried out basically as above with the
exception that unlabeled probe was added to the reaction in 20–80-fold
molar excess as compared with the labeled probe. Both the probe and an
unlabeled competitor were added to the reaction at the same time and
then incubated and electrophoresed as before. For these experiments,
the unlabeled competitor in each reaction was the same double-
stranded oligonucleotide as the probe used in that reaction.
RESULTS
Cell-specific Transcription of the Mouse VCAM-1 Is Regu-
lated by the 5-Upstream Flanking Sequences—The naturally
occurring Sox18 mutations in mice and humans (15, 20) display
defects in hair and skin development. However, the most life
threatening is the generalized edema caused by lymphatic vas-
cular dysfunction (17–19). Hence, we were particularly inter-
ested in the identification of Sox18 target genes that play a role
in lymphatic function and thus may allow us to better under-
stand the molecular basis of the ragged phenotype.
We hypothesized that VCAM-1 was regulated by SOX18.
Therefore, to test this supposition we examined the ability of
VCAM-1 promoter sequences to direct the expression of the
LUC gene in muscle, endothelial, and fibroblast cells. For this
purpose, we designed primers to amplify the complete pub-
lished murine VCAM-1 sequence (46) and cloned the sequenced
amplified product into the promoterless pGL2-Basic luciferase
reporter vector. This plasmid was denoted as PGL2-VC1889
and encompasses 1889 bp immediately upstream of the murine
VCAM-1 translation start codon (Fig. 1). To test if Sox18 could
trans-activate the VCAM-1 promoter, we transfected it into
fibroblasts and endothelial and skeletal muscle cell lines (Fig.
2). Transfection of pGL2-VC1889 into COS-1 fibroblasts and
SVEC4-10 high venule endothelial cell lines demonstrated that
the upstream promoter sequences of the VCAM-1 gene confer
high level expression in a cell-specific manner. For example,
pGL2-VC1889 activity in COS-1 fibroblasts is  5-fold greater
than that of pGL2-Basic and 100-fold less than that of the
constitutively active SV40 promoter. In contrast, in endothelial
SVEC cells pGL2-VC1889 activity is 50-fold greater than
that of pGL2-Basic and is similar in activity to the very
efficient SV40 promoter. This is consistent with our previous
study that reported a high level of Sox18 expression in the
nuclei of SVEC4-10 (48). Similarly, when the VCAM pro-
moter was transfected into proliferating C2C12 myoblasts,
the VCAM-1 promoter activity was 50-fold greater than
that of pGL2-Basic (data not shown), as has been reported
previously (44). In conclusion, the efficient cell specific ex-
pression of VCAM-1 is consistent with the in vivo expression
profile of VCAM-1.
FIG. 1. Schematic representation of
the murine VCAM-1 promoter and
the positions of elements important
for this study. A schematic diagram of
the full-length VCAM-1 promoter con-
struct cloned and used in this investiga-
tion is shown. Of particular note are the
three putative Sox binding sites displayed
as bold boxes and denoted as SoxA, SoxB,
and SoxC. The core heptameric Sox se-
quence is displayed below each box with
an arrow to indicate the direction of each
binding site as compared with the direc-
tion of transcription. All numbers desig-
nate important elements or clones re-
ferred to in the text. Luc refers to the
luciferase reporter gene, F1 ori denotes
the origin of replication of filamentous
phage for generation of single-stranded
DNA, and Amp represents the ampicillin-
resistance gene.
FIG. 2. VCAM-1 promoter regulates transcription in a cell/tis-
sue-specific manner. The activity of the full-length VCAM-1 pro-
moter in COS-1 fibroblast (left) and SVEC4-10 endothelial (right) cells
is depicted. pGL2 control (pGL2C), driven by the promiscuous SV40
enhancer and early promoter, was used as a control for transfection
efficiency and as a comparison for the level of cell-specific activity of the
VCAM-1 promoter. pGL2-Basic (pGL2) is the empty luciferase vector,
whereas VC1889 refers to 1889 bp of the murine VCAM-1 promoter
cloned into pGL2B. 2 g of each plasmid was transfected in all cell lines
using a liposome-mediated procedure. Results are expressed as mean
S.D. of two sets of independent quadruplicates.
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The VCAM-1 Gene Is a Target of the Sry-related HMG Box
Gene Sox18 as Shown by the Identification of Three SOX18
Binding Sites—VCAM-1 expression can be stimulated via cy-
tokines (e.g. tumor necrosis factor-) (43), mitogens (e.g. vas-
cular endothelial growth factor) (49), and transcription factors
(e.g. IRF-2 and Oct-1) (42, 43). We investigated whether
SOX18, could trans-activate the mouse VCAM-1 promoter in
COS-1 fibroblasts. Co-transfection of a Sox18 expression con-
struct with the pGL2-VC1889 promoter resulted in a moderate
5-fold activation (Fig. 3A). This activation is dose-dependent, as
increasing amounts of Sox18 augmented the trans-activity of
the VCAM-1 promoter (Fig. 3B). Thus, we demonstrate here for
the first time that Sox18 trans-activates the promoter of
VCAM-1.
SOX and SRY proteins contain HMG domains that bind DNA
in a sequence-specific manner. These proteins have been re-
ported to bind in vitro and in vivo to sites with a core motif
resembling (A/T)(A/T)CAA(A/T)G (for review, see Ref. 11). We
have reported previously that SOX18 can bind and trans-acti-
vate a core consensus motif of AACAAAG (12). As an initial
step in the investigation to examine whether SOX18 was able
to bind the murine VCAM-1 promoter, we searched the se-
quence of the promoter using MatInspector (50) and found
three potential Sox binding sites (Fig. 1). Of these, the two at
491 (SoxC) and 1569 (SoxA) contain a perfect core consen-
sus site (AACAAT) for the binding of Sox/Sry transcription
factors. The core sequence of the site at 715 (SoxB) is slightly
different from the consensus, with a G at position 1 (GACAAT).
Interestingly, it has been reported that SOX17 can bind this
sequence from a pool of otherwise random oligonucleotides (51).
To investigate whether GST-SOX18 can interact with the
putative SoxA, SoxB, and SoxC binding sites, we performed an
EMSA using 32P-labeled oligos that consist of the Sox binding
site in addition to some surrounding sequence (see “Materials
and Methods”). As seen in Fig. 4A, the SOX18 protein bound
strongly to all three putative Sox sites. In contrast, GST pro-
tein alone could not bind to any of the three oligonucleotides
used in this study. Thus, SOX18 can potentially interact with
all three sites in the VCAM-1 promoter. To examine the se-
quence-specificity of the protein-DNA interaction, we at-
FIG. 3. Sox18 activates the VCAM-1 promoter. A, co-transfection
of COS-1 cells with control vectors (pSG5, an expression vector and
pGL2B, a luciferase reporter vector) and with pSG5 containing Sox18
(Sox18) and pGL2B containing 1889 bp of the proximal mVCAM-1
promoter (VC1889). B, co-transfection of increasing amounts of Sox18
leads to the dose-dependent expression of the mVCAM-1 reporter
(VC1889). 1, 2, and 3 g of Sox18 expression vector were transfected in
lanes 2–4, 6 and 7, and 8, respectively (counting from the left). The
results are expressed as the mean  S.D. of at least two independent
quadruplicates.
FIG. 4. Sox18 binds to multiple sites in the VCAM-1 promoter.
A, a bacterially produced GST-Sox18 fusion protein binds strongly as a
single band to all putative Sox sites in the VCAM-1 promoter (arrow).
Lanes 1–3 (counting from the left) delineate that the GST protein alone
can not contribute to the binding of these oligonucleotides. All oligos
were 32P-radiolabeled, combined with GST-Sox18, and then electro-
phoresed on 6% polyacrylamide gels. B, EMSA competition assays with
up to 50-fold molar excess of “cold” unlabeled oligos were used delineate
the specificity of SOX18 binding to the Sox motifs.
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tempted to compete the binding with cold/unlabeled double-
stranded oligonucleotide with the same sequence as the probe
used in the reaction. Fig. 4B demonstrates that these se-
quences effectively competed for the formation of the SOX18-
DNA complex. These experiments reveal that SOX18 binds in
an efficient and sequence-specific manner to all three putative
Sox sites.
The Sox B site at715 bp Is Essential for trans-Activation by
Sox18—In an attempt to further elucidate which sites were
necessary for the in vivo trans-activation of VCAM-1 in fibro-
blast cells, we produced a series of 5 unidirectional deletions in
the mVCAM-1 promoter. Three deletion constructs were pro-
duced, namely pGL2-VC1215, pGL2-VC754, and pGL2-VC504,
which contained 1215, 754, and 504 nucleotides, respectively,
of 5 flanking sequences cloned upstream of the luciferase
reporter in pGL2-Basic.
By transfecting the full-length and deleted promoters in the
absence/presence of the Sox18 expression vector in COS-1 cells,
we could demonstrate that VC1889, VC1215, and VC754 were
trans-activated by SOX18 (Fig. 5A). In contrast, deletion of the
sequences from 715 to 504 completely ablated SOX18-me-
diated trans-activation. This suggested that the cognate Sox18
binding site at 715 was necessary for trans-activation. More-
over, the most proximal Sox binding site (504 bp) could not
independently support or mediate trans-activation. Interest-
ingly, the sequences between 1889 and 715 seem to contain
elements that confer repression of the activity of the VCAM-1
promoter. This repressive activity may be due to the putative
octamer sites present in this region.2
To directly identify which of the two potential Sox sites in the
VCAM-1 promoter at 1569 and 715 bp are necessary for
Sox18 mediated trans-activation, we used site-directed mu-
tagenesis (Fig. 6A). Two bases in the middle of each of the
heptameric Sox sites were mutated (Fig. 6D). Transfection of
the clone VC1889-mSoxA (Fig. 6, B, and C) demonstrated that
the mutation of the distal SoxA binding site at 1569 did not
compromise Sox18-mediated trans-activation of the VCAM-1
promoter. In dramatic contrast, mutation of Sox site B at 715
bp in the construct VC1889-mSoxB, completely abrogated the
basal activity of the promoter and also ablated the Sox18-
mediated trans-activation of the murine VCAM-1 promoter.
These results, in addition to those from the deletion experi-
ments, show that the SoxB site at 715 bp in the murine
VCAM-1 promoter is necessary for trans-activation by Sox18.
The functional analysis correlated with the in vitro binding
data. For example, we examined the ability of the mutant
mSoxA and mSoxB motifs (Fig. 6D) to compete for SOX binding
relative to the wild type motifs in EMSA competition assays.
Fig. 6E demonstrates that the ability of the mutated Sox motifs
to compete for SOX binding is certainly compromised relative
to the native motifs. Fig. 6F demonstrates that even at 80-fold
molar excess the mutated sequences very inefficiently compete
for SOX protein binding. These experiments demonstrate that
SoxB is necessary for trans-activation by Sox18 and that sig-
nificant trans-activation of the VCAM-1 promoter by Sox18 is
associated with efficient binding to the SoxB motif.
The ragged Alleles of SOX18 Cannot trans-Activate VCAM-1
Expression—We have reported previously that Sox18 is mu-
tated in all four alleles of ragged (Ra, RaJ, Ragl, and RaOP).
ragged is a mouse mutant that displays hair follicle, vascular,
and lymphatic abnormalities (10, 15). All four mutants consist
of a missense mutation that occurs in the activation domain (aa
252–345) for Ra (aa 313), RaJ (aa 312), and Ragl (aa 323),
whereas the RaOP (aa 349) mutation is 4 bp C-terminal of this
2 B. M. Hosking, personal observation.
FIG. 5. Deletion analysis defines the cis-acting region between
754 and504 as important in Sox18-mediated trans-activation
in all cell lines tested. A, schematic representation of the deletion
constructs. B, pGL2-Basic and the unidirectional deletion constructs of
the VCAM-1 promoter cloned into pGL2-Basic were co-transfected into
COS-1 fibroblasts with either pSG5 (empty vector) or pSG5-Sox18.
Relative luciferase activity is compared with the luciferase activity
obtained after co-transfection of pGL2-Basic with pSG5 (empty vector
alone) and arbitrarily set to 1. C, the data from panel B is re-presented
as the fold activation of the VCAM-1 promoter constructs by Sox18. Fold
activation is expressed relative to the activation of the empty luciferase
vector, pGL2-Basic, and co-transfected with the expression vector,
pSG5-Sox18, which was arbitrarily set to 1. The mean luciferase fold
activation values and S.D. values were derived from 2–3 independent
quadruplicates.
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domain. After the frameshift mutation, all alleles encode non-
sense protein until it truncates at aa 435 (15). In an effort to
gain a better understanding of the molecular events occurring
at the VCAM-1 promoter, we investigated the effect of the
ragged constructs in co-transfection with the VCAM-1
promoter.
FIG. 6. Site-directed mutation analysis identifies the Sox binding site B (715 bp) as important in Sox18-mediated trans-
activation of the VCAM-1 promoter in all cell lines tested. A, schematic representation of the mutated constructs. The bold boxes with crosses
represent the mutated (m) putative Sox binding sites. B, pGL2Basic and the site-directed mutations (m) of the VCAM-1 promoter cloned into
pGL2Basic were co-transfected into COS-1 fibroblasts with pSG5 (empty vector) or pSG5-Sox18 (Sox18). Relative luciferase (Luc.) activity is
compared with the luciferase activity obtained after transfection of pGL2Basic with the empty vector pSG5 and arbitrarily set to 1. C, the data from
B is re-presented as the fold activation of the VCAM-1 promoter constructs by Sox18. Fold activation is expressed relative to the activation of the
empty luciferase vector pGL2Basic co-transfected with the expression vector pSG5-Sox18, which was arbitrarily set to 1. The mean luciferase fold
activation values and S.D. values were derived from 2–3 independent quadruplicates. D, schematic describing the native (wt) and mutated (m)
SoxA and B motifs. E and F, EMSA competition assays with 20–80-fold molar excess, demonstrating that the mutated oligos are unable to
efficiently compete for SOX18 binding. wt, wild type.
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Transfection analysis in fibroblasts using the full-length
VCAM-1 promoter demonstrate the inability of the four alleles
of ragged, Ra, RaJ, Ragl, and RaOP, to trans-activate the
VCAM-1 promoter as compared with wild type Sox18 (Fig. 7A,
lanes 12–16). Furthermore, co-transfection of the VCAM re-
porter construct with equal amounts of wild type Sox18 and
any of the four ragged mutants leads to complete repression of
VCAM-1 trans-activation, suggesting that these mutants act in
a dominant-negative fashion. This result is also observed in
endothelial and skeletal muscle cells (data not shown).
VCAM-1 Expression in Lung, Skeletal Muscle, and Skin Is
Significantly Reduced in the ragged Mouse—The phenotype of
ragged mice, abnormal lymphatic system and hair follicles, is
similar to that of humans with the disorder referred to as
hypotrichosis-lymphedema-telangiectasia (20). Our in vitro
and transfection analysis established Sox18 as crucial for the
trans-activation of VCAM-1 expression in cells and show that
ragged proteins target and prevent VCAM-1 activation by
Sox18.
Of the four alleles of ragged, RaOP is the most deleterious to
the survival of the offspring. The RaOP heterozygotes resemble
the homozygotes of the other three allelic forms and generally
display a hairless and edematous phenotype (52, 53). There-
fore, we utilized the RaOP mouse model to investigate the in
vivo effect of this mutant form of Sox18 on the expression levels
of VCAM-1. By using real time RT-PCR with RNA from lung,
skin, and skeletal muscle, organs which exhibit high expres-
sion of Sox18 and VCAM-1 (10, 26–30, 48), we demonstrated
aberrant VCAM-1 expression in this mutant. Fig. 8 vividly
demonstrates the effect that the RaOP mutation exerts on the
expression of VCAM-1 in these tissues. In the wild type lung,
VCAM-1 is abundantly expressed, in contrast to the mutant
animal, which expresses 5-fold less. Moreover, the RaOP mu-
tation extensively abrogates expression of VCAM-1 in skeletal
muscle and skin, with levels of repression up to almost 40-fold
(the data and normalization are described in Table I). More-
over, the specificity of aberrant VCAM-1 mRNA expression in
the ragged mouse is highlighted by our observation that
ICAM-1 and 2, JCAM, NCAM-1, and PECAM-1 mRNA ex-
pressions are unaffected in Ra animals (data not shown). Thus,
the in vivo evidence is in strong concordance with the in vitro
and cell culture analyses. In conclusion, we provide strong
evidence that the VCAM-1 gene is a primary target of SOX18
and that its expression is significantly compromised by all
ragged Sox18 mutant proteins.
DISCUSSION
We present evidence that Sox18 regulates the expression of
the important VCAM-1 that parallels the pattern of expression
of Sox18. VCAM-1 is involved in the inflammatory response,
and its aberrant regulation and/or expression has been impli-
cated in edema and atherogenesis.
This validated our Sox18 target gene rationale based on
overlapping spatio-temporal expression profiles. For example,
the Sox18 gene is expressed in the vasculature, hair follicle,
allantois, and the yolk-sac blood islands during embryogenesis
(10) with wide ranging expression in the adult, notably in the
lung and hind limb skeletal muscle (45). This rationale was
further developed by an examination of the ragged mouse ab-
normalities. The four allelic variants of the Ra phenotype are
characterized by hypotrichosis (54), chylous ascites, and edema
from mesenteric lymphatic dysfunction (18, 19), consistent
with aberrant VCAM-1 expression. Moreover, VCAM-1 is an
important counter receptor or ligand for 4 integrins (31) and is
expressed in the developing allantois, the mesoderm of the yolk
sac, and the hematopoiesis sites in the yolk sac (32, 55), similar
to Sox18. Furthermore, VCAM-1 is expressed in multiple or-
gans (56) and has an important role in skeletal muscle (28, 29)
and blood vascular and lymphatic endothelia (46, 57–59).
We observed that the murine VCAM-1 promoter demon-
strated cell-specific transcription in a manner similar to that
reported previously (43, 44). We identified three potential Sox
binding sites in the VCAM-1 promoter and utilized EMSA
assays to show that Sox18 bound efficiently and in a sequence-
specific manner to all three potential Sox binding sites. How-
ever, a series of 5 unidirectional deletions and mutagenesis
demonstrated that the SoxB motif is necessary and critical for
SOX18-dependent trans-activation and basal expression of the
VCAM-1 promoter.
The effect of mutation at the SoxB site at nucleotide position
715 bp on basal activity in the cell types tested was an
unexpected aspect of this investigation, as it has been previ-
ously reported that expression of the human VCAM-1 promoter
is dependent on the IRF-2 element in muscle (44). This element
is positioned between the TATA box at 32 bp and the trans-
lation start site in the human promoter (42). Furthermore, the
IRF-2 site is conserved in the murine promoter in the same
region.2 Our study suggests that, in the context of the first 1889
bp of murine VCAM-1 promoter, the SoxB binding site at 715
bp is necessary and sufficient for the basal and Sox18-activated
expression of VCAM-1 in fibroblasts, endothelial, and skeletal
muscle cells.
In the context of understanding the Ra phenotype, we ob-
served all ragged allelic forms of mutant SOX18 (Ra, RaJ,
Ragl, and RaOP) failed to activate the VCAM-1 promoter.
Furthermore, the ragged forms of SOX18 have the ability to
ablate the trans-activation of VCAM-1 expression in the pres-
ence of native SOX18. These results suggest that ragged
SOX18 proteins act in a dominant negative fashion, i.e. they
are able to interfere with the role of the wild type protein. A
similar situation has been reported for the Sox10 mutation in
the human disease called the Waardenburg syndrome (60, 61),
which results in the expression of a protein that is prematurely
truncated shortly after the HMG box. This mutant has been
shown to act in a dominant negative fashion by virtue of its
FIG. 7. The ragged SOX18 protein compromises the expression
and activation of the VCAM-1 promoter in all cell lines tested. A,
COS-1 cells were co-transfected with the empty luciferase vector
pGL2Basic or the VCAM-1 promoter cloned into pGL2-Basic (pGL2-
Basic-VC1889) and the empty vector pSG5 or pSG5 constructs driving
the expression of wild type Sox18 or Ra, RaJ, Ragl, or RaOP. The
results are expressed as the mean  S.D. of 2–3 independent
quadruplicates.
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ability to bind to but not activate the Mitf promoter (62),
resulting in reduced levels of endogenous MITF protein. This
causes the hypopigmentation and deafness associated with the
Waardenburg syndrome. In a similar fashion to the SOX10
mutant, the ragged proteins bind to the DNA but do not trans-
activate the expression of the VCAM-1 promoter. In addition to
competing for binding sites, the ragged proteins may act
through a slower rate of turnover as compared with the wild
type, or they may sequester co-factors that are in limited sup-
ply. All of these modes of action would render the wild type
protein unable to activate the VCAM-1 promoter and would be
interpreted as a dominant negative effect.
It is hypothetically possible that expression of the ragged
proteins may compromise the activity of other SOX proteins.
Wegner (11) has stated that many SOX proteins have overlap-
ping expression patterns and, in a few cases, it has been reported
that multiple Sox factors can control the expression of the same
genes in the same tissues. Thus, there is the distinct possibility
that multiple SOX proteins can modulate the activity of VCAM-1
in endothelia and elsewhere where ragged is expressed. This
leads us to the hypothesis that ragged may interfere with the
ability of other SOX proteins to modulate the activity of VCAM-1,
and this hypothesis is currently under investigation.
In choosing to study VCAM-1, we were interested in eluci-
dating aspects of the molecular mechanisms mediating edema
in ragged mice and in humans with HLT syndrome. It has been
reported that an overexpression of VCAM-1 leads to inflamma-
tion and an edema that is characterized by an immune infil-
trate (63–65). The ragged animal has been characterized with
an edematous phenotype, and, yet, we have demonstrated here
a marked reduction in the level of VCAM-1 expression. This
suggests that the edema present in the ragged animal may not
be linked to the expression of VCAM-1. If this were indeed the
case, then it could be expected that the fluid retained in the
interstitial spaces of the ragged animal would not consist of
immune infiltrate. In agreement with this hypothesis, Wallace
(19) has reported that the composition of the chyle present in
some of the ragged homozygous neonates contained very few
monocytes and macrophages. This conclusion is also supported
by the fact that no edema was reported in mice targeted for
VCAM-1 (35). These results suggest that misregulation of
VCAM-1 is not the source of the edema and that, potentially,
the lack of immune cells in the chyle of the RaOP animals may
be due to the repression of VCAM-1 on the endothelia of the
lymphatics. However, we cannot rule out that edema is the
result of aberrant VCAM-1 expression, including overexpres-
sion or repression/ablation.
In conclusion, we show that SOX18 is essential for the expres-
sion of the cell adhesion molecule VCAM-1 (and not other adhe-
sion molecules) in cell culture and animal models. The uncon-
trolled overexpression of VCAM-1 is associated with many
chronic immune diseases such as atherosclerosis, arthritis, and
asthma (66–68). In fact, much literature now reports the use of
drugs that modulate VCAM-1 expression to successfully reduce
immune infiltrate and the consequent edema in many diseases
(69–71). We have shown that the 715 bp SoxB binding site
regulates the VCAM-1 promoter activity and suggest that this
site and Sox18 are therapeutic targets for the modulation of
VCAM-1 expression and the control of inflammation.
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FIG. 8. Real time quantitative RT-
PCR comparison of VCAM-1 expres-
sion in wild type and ragged adult
male sibling pairs. The high expression
tissues, lung, skin, and hind limb muscle
were chosen for investigation of VCAM-1
expression levels. The levels of VCAM-1
mRNA were normalized and expressed
relative to cyclophilin and calculated as
displayed in Table I.
TABLE I
Raw real time data
This table demonstrates the calculation of relative levels of VCAM-1
from the raw real time RT-PCR data, carried out according to manu-
facturer’s instructions.
Samplea Ctb Ctc Rel. expr.d (104)
Wt lung cyclo 15.8
RaOP lung cyclo 15.9
Wt sk. mu. cyclo 17.4
RaOP sk. mu. cyclo 18.3
Wt Skin cyclo 16.9
RaOP skin cyclo 17.8
Wt lung VCAM 22.3 6.5 109.9  0.3
RaOP lung VCAM 25.3 9.4 14.4  0.36
Wt sk. mu. VCAM 24.8 7.5 55.4  1.2
RaOP sk. mu. VCAM 31.1 12.7 1.5  0.045
Wt skin VCAM 28.9 12 2.4  0.023
RaOP skin VCAM 34.3 16.5 0.1  0.00092
a Wt, wild type; cyclo, cyclophilin; sk. mu., skeletal muscle.
b Ct, crossing threshold.
c Ct, control crossing threshold  sample crossing threshold.
d Rel. Expr., relative expression (2(Ct)).
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